{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:39:49Z","timestamp":1759207189049,"version":"3.38.0"},"reference-count":10,"publisher":"JLE","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Dermatol"],"published-print":{"date-parts":[[2018,1,1]]},"DOI":"10.1684\/ejd.2017.3169","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:11:23Z","timestamp":1696864283000},"page":"115-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A case of malignant melanoma with multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy"],"prefix":"10.1684","volume":"28","author":[{"given":"Takeshi","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Nishigori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"3169_CR1","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/1346-8138.13338","volume":"43","author":"N. Yamazaki","year":"2016","unstructured":"Yamazaki N, Uhara H, Wada H, et al. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma. J Dermatol 2016; 43: 1146\u201353.","journal-title":"J Dermatol"},{"key":"3169_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","volume":"372","author":"A.M. Eggermont","year":"2008","unstructured":"Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117\u201326.","journal-title":"Lancet"},{"key":"3169_CR3","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/ced.13179","volume":"42","author":"T. Yanagi","year":"2017","unstructured":"Yanagi T, Hata H, Homma E, Kitamura S, Imafuku K, Shimizu H. Adjuvant therapy with low-dose interferon-beta for stage II and III melanoma: results of a retrospective analysis. Clin Exp Dermatol 2017; 42: 781\u20135.","journal-title":"Clin Exp Dermatol"},{"key":"3169_CR4","first-page":"2305","volume":"122","author":"Y. Fujisawa","year":"2012","unstructured":"Fujisawa Y, Otsuka F, Japanese Melanoma Study Group F. Does adjuvant therapy improve the prognosis of stage II and stage III melanoma patients? An analysis of 831 cases. Jpn J Dermatol 2012; 122: 2305\u201311.","journal-title":"An analysis of 831 cases. Jpn J Dermatol"},{"key":"3169_CR5","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1111\/jdv.12040","volume":"27","author":"T. Matsumoto","year":"2013","unstructured":"Matsumoto T, Yokota K, Sawada M, et al. Postoperative DAVIFN-therapy does not improve survival rates of stage II and stage III melanoma patients significantly. J Eur Acad Dermatol Venereol 2013; 27: 1514\u201320.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3169_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/CMR.0b013e32835e7713","volume":"23","author":"M.R. Roh","year":"2013","unstructured":"Roh MR, Zheng Z, Kim HS, Jeung HC, Rha SY, Chung KY. Difference of interferon- and interferon-on melanoma growth and lymph node metastasis in mice. Melanoma Res 2013; 23: 114\u201324.","journal-title":"Melanoma Res"},{"key":"3169_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1089\/107999003772084860","volume":"23","author":"D.W. Leaman","year":"2003","unstructured":"Leaman DW, Chawla-Sarkar M, Jacobs B, et al. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2. J Interferon Cytokine Res 2003; 23: 745\u201356.","journal-title":"J Interferon Cytokine Res"},{"key":"3169_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.celrep.2016.03.006","volume":"15","author":"Y.V. Katlinskaya","year":"2016","unstructured":"Katlinskaya YV, Katlinski KV, Yu Q, et al. Suppression of type I interferon signaling overcomes oncogene-induced senescence and mediates melanoma development and progression. Cell Rep 2016; 15: 171\u201380.","journal-title":"Cell Rep"},{"key":"3169_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.cyto.2016.01.010","volume":"89","author":"A. Ortiz","year":"2017","unstructured":"Ortiz A, Fuchs SY. Anti-metastatic functions of type 1 interferons: foundation for the adjuvant therapy of cancer. Cytokine 2017; 89: 4\u201311.","journal-title":"Cytokine"},{"key":"3169_CR10","doi-asserted-by":"publisher","first-page":"e1047584","DOI":"10.1080\/2162402X.2015.1047584","volume":"4","author":"A. Kakizaki","year":"2015","unstructured":"Kakizaki A, Fujimura T, Furudate S, et al. Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages. Oncoimmunology 2015; 4: e1047584.","journal-title":"Oncoimmunology"}],"container-title":["European Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2017.3169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1684\/ejd.2017.3169\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2017.3169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2017.3169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:21:09Z","timestamp":1741191669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2017.3169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,1]]}},"alternative-id":["3169"],"URL":"https:\/\/doi.org\/10.1684\/ejd.2017.3169","relation":{},"ISSN":["1952-4013"],"issn-type":[{"type":"electronic","value":"1952-4013"}],"subject":[],"published":{"date-parts":[[2018,1,1]]},"assertion":[{"value":"3 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}